On-Demand Content | Virtual Event
Marni Edelhart, VP, Content, MOMENTUM EVENTS
As psychedelics continue to move from the fringes to increasingly popular acceptance, government officials are beginning to put their influence behind Them. This session offers a first hand perspective from an elected official about putting forth a pro-psychedelic and empathogen bill.

  • How state mandates and support can drive progress
  • The role of state-sponsored research in drug policy reform
  • The need to differentiate clinical vs recreational use
Alex Dominguez, State Representative, STATE OF TEXAS
Popular agreement suggests that the legal future of psychedelics will take place in the clinical as opposed to the recreational realm. Therefore, clinical trials and research will be very key to expanding access and understanding how these treatments actually affect our brains.

  • What have we learned from the latest clinical trials
  • Who is funding the research
  • Where are the gaps in understanding that need more study
Nolan Williams MD, Assistant Professor of Psychiatry & Behavioral Science, STANFORD UNIVERSITY
The psychedelic renaissance is receiving an incredible amount of interest from biotech investors who see psychedelic molecules as the next wave in treating neuropsychiatric disorders. But investors who are assessing this opportunity solely through the lens of biotech may not be seeing the full picture. Psychedelic medicine will challenge many long held conventions of medicine from their off-label uses, to the mainstream cultural impact to their deep integration with experience. All of these change the conversation for the future of psychedelics and biotech, and ought to be considered for any investor looking to allocate capital to the space.

Ronan Levy, Executive Chairman, FIELD TRIP VENTURES
Lucia Huang, Co-Founder & CEO, OSMIND
Carlene MacMillan, CEO & Founder, BROOKLYN MINDS
Owen Muir MD, Chief Innovation Officer, BROOKLYN MINDS

Jon Purow, Counsel, ZUBER LAWLER
One thing that most psychedelic enthusiasts and researchers can agree on is that anyone experimenting with or being treated with psychedelics or empathogens need support to do so safely and effectively. This session will examine the potential for a community-driven approach to psychedelics that ensures:
  • More access to support and information about psychedelics
  • A strong base of advocates for psychedelic access
  • Increased educational resources about psychedelics
Mackenzie Bullard, Community Engagement Facilitator, BOSTON MEDICAL CENTER
The path forward for Psychedelics will not mirror that of Cannabis, but one similarity is the extreme growth the industry is seeing that at some point will face a dip. Some of that dip will come in the form of mergers and acquisitions. This session will address:
  • The potential for a “bubble” in Psychedelic Start-Ups
  • What CBD and Cannabis can teach us about risks to growth
  • Where Will Long Term Success Be Found for Psychedelics
Benton Bodamer, Member, DICKINSON WRIGHT
Hilary Bricken, Partner, HARRIS BRICKEN
Daniel Carcillo, Former NHL player, Founder, WESANA HEALTH
Mason Marks, MD, Attorney, HARRIS BRICKEN
Benjamin Lightburn, CEO and Co-Founder, FILAMENT HEALTH
Join Dr. Joseph Tucker for a deep dive into the current landscape of derivative psychedelic and empathogenic molecules and their potential to enhance and advance treatments of mental and behavioral issues.
This session offers:
  • An introduction to the proprietary technology behind specific derivative molecules
  • The revenue models driving the development of derivative molecules
  • Insight into the role of derivative molecules in the future of Brain Health
Joseph Tucker MD, President & CEO, MAGICMED
The dramatic results offered by psychedelic treatments can have the adverse effect that care ends after a single therapeutic interaction. Even though patients may feel relief from their trauma or mental illness, however, they often still need support to move forward.

This session will cover:
  • Post-treatment support strategies
  • Warning signs for clients who may experience post-treatment stress
  • Collaborative approaches for building a more supportive approach to psychedelics
Marni Edelhart, VP, Content, MOMENTUM EVENTS
In 2020, Oregon became the first state in the nation to create a Psilocybin therapy program. However, the passage of Measure 109 was only the first step. Sam Chapman was the Campaign Manager for Measure 109 and is now guiding the development of rules and regulations over the next two years to create the most affordable, accessible, equitable program possible.

This session will provide:
  • A brief overview of what Measure 109 does and does not do
  • Applicable lessons learned for states considering the psychedelic therapy model
  • An overview of what the next two years of rulemaking in Oregon will entail
Sam Chapman, Executive Director, THE HEALING ADVOCACY FUND
Michael Pollan’s popular book about psychedelics and empathogens is titled “How to Change Your Mind” because these treatments have the potential power to truly change the ways in which we think and how our brains work. Therefore, perhaps we could look at implementing them not only to treat trauma, but to help prevent it by treating the hurtful impulses that cause it.

This session will cover:
  • Psychedelics and the treatment of layered, complex trauma
  • The potential of Psychedelics to shift a racist mindset
  • Business models that create more inclusive access
Nicole Buchanan, Professor of Psychology, MICHIGAN STATE UNIVERSITY
Investment in psychedelics and empathogens has increased so much that many funds are actually focused solely on this industry. Therefore, both investors and start-ups need to be especially critical about where they are investing and/or seeking their funds.

During this session:
  • Hear from active investors about how they evaluate potential investments
  • Tap into a risk profile view of investments in this space
  • Learn how to make your start-up stand out when pitching investors
Amanda Eilian, Co-Founder, ABLE PARTNERS

Stephen Hays, Founder, WHAT IF VENTURES
Holly Jacobus, Investment Partner, JOYANCE & SOCIAL STARTS
Tim Schlidt, Co-Founder & Partner, PALO SANTO
Sonia Weiss, General Partner, WPSS INVESTMENTS
In recent years there has been increasing interest in use of psilocybin for relief of a variety of challenging mental health conditions, including anxiety and depression at the end of life.

This session will address:
  • An innovative effort to remove barriers to access to psilocybin therapy for seriously ill patients under Right to Try laws: AIMS et al v DEA. Kathryn Tucker is lead counsel in this first of its kind litigation seeking to compel DEA to allow access under RTT. One of the nation’s foremost patient rights advocates, Tucker will discuss the litigation and how a successful outcome will open access nationwide.
Kathryn Tucker, Co-Chair Psychedelic Practice, Emerge Law Group, and Founding Member, PSYCHEDELIC BAR ASSOCIATION
Posttraumatic stress disorder (PTSD) is a prevalent mental health condition with substantial impact on daily functioning that lacks sufficient treatment options. Previous research has led to the U.S. FDA’s designation of 3,4-methylenedioxymethamphetamine (MDMA) as a Breakthrough Therapy for treatment of PTSD when administered as an adjunct to therapy. Findings of the first randomized, double-blind, Phase 3 trial assessing the efficacy and safety of 3 sessions with a divided single-dose of MDMA or placebo to participants with severe PTSD (n = 90) will be presented. Results from primary and key secondary endpoints, effect size, and a responder analysis will be presented. Risk/benefit considerations and cost effectiveness analyses will be explored.

Berra Yazar-Kolinski Ph.D., Chief Scientific Officer, MAPS PBC
Daniel Carcillo, Former NHL player, Founder, WESANA HEALTH
A growing number of clinical research sponsors are competing to get psychedelic drug products to market. Many CMOs are engaged in supply exclusivity, creating a bottleneck of material scarcity. The Psygen team will share their insights, understanding of the current market demands and what it will take to accelerate the development and access to psychedelic APIs.

Danny Motyka, Chief Executive Officer, PSYGEN INDUSTRIES LTD.
Nadia Van der Heyden, Director of Sales and Marketing, PSYGEN INDUSTRIES LTD.
David Wood, Chief Legal Officer and General Counsel, PSYGEN INDUSTRIES LTD.
The growth of psychedelics stems from a growing understanding that we have only just begun into brain health and how to improve it. This session will use Psychedelics as a jumping off point for a broader look at trends shaping the future of brain health.


Sharmin Ghaznavi MD, Associate Director, Center for the Neuroscience of Psychedelics, MASS GENERAL HOSPITAL
Joseph Tucker, MD, President & CEO, MAGICMED
Greg McKee, Chairman and CEO, TRYP THERAPEUTICS

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Privacy Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.